saracatinib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Saracatinib (AZD-0530) is an experimental drug being developed by AstraZeneca. It acts as a dual kinase inhibitor, with selective actions as a Src inhibitor and a Bcr-Abl tyrosine-kinase inhibitor.   Wikipedia

Chemistry

  • SMILES: CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
  • InChIKey: OUKYUETWWIPKQR-UHFFFAOYSA-N
  • Mol. Mass: 542.04
  • ALogP: 3.94
  • ChEMBL Molecule:
    saracatinib  
More Chemistry

Pharmacology

Alternative names

4-quinazolinamine, n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1- piperazinyl)ethoxy)-5-((tetrahydro-2h-pyran-4-yl)oxy)- | az-10353926 | azd0530 | azd 0530 | azd-0530 | azd0530 difumarate | n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1-piperazinyl)ethoxy)-5-(tetrahydro-2h-pyran-4-yloxy)-4-quinazolinamine | n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2h-pyran-4-yloxy)quinazolin-4-amine | n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-((tetrahydro- 2h-pyran-4-yl)oxy)quinazolin-4-amine bi((2e)-but-2-enedioate) | saracatinib | saracatinib difumerate

Organizations (46)

Research & Development (46)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (44)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (44)


 

Adenocarcinoma (Phase 2)

Alcohol Drinking (Phase 2)

Alcoholism (Phase 1)

Alzheimer Disease (Phase 2)

Bone Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Breast Neoplasms, Male (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Verrucous (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Dermatofibrosarcoma (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2/Phase 3)

Fibrosarcoma (Phase 2)

Graft vs Host Disease (Phase 2)

Hamartoma (Phase 2/Phase 3)

Healthy Volunteers (Phase 1)

Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)

Leiomyosarcoma (Phase 2)

Liposarcoma (Phase 2)

Lung Neoplasms (Phase 2)

Lymphangioleiomyomatosis (Phase 2)

Melanoma (Phase 2)

Myositis Ossificans (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2/Phase 3)

Pancreatic Neoplasms (Phase 2)

Parkinson Disease (Early Phase 1)

Pleural Effusion, Malignant (Phase 2)

Prostatic Neoplasms (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Endometrial Stromal (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Thymoma (Phase 2)

Tongue Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 35
  • # of Trial Organizations: 46

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue